Skip to main content
SpringerLink
Log in

Screening for prostate cancer in african americans

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

African American men are known to have a higher risk of developing prostate cancer. Historically, African American men have presented at a higher stage and had a worse outcome from the disease than non-African American men. There is an ongoing debate whether this disparity is due to biologic, environmental, or behavioral factors, or a combination of these factors. Furthermore, lack of access to care is implicated. Despite this debate, there is emerging data that African American men and their families are receptive to education and early detection. Encouraging data from the military, Veteran’s Administration, and private sector suggest that African American men can have a similar outcome to non-African American men if diagnosed early and treated effectively. Early detection efforts depend on prostate-specific antigen (PSA) testing. This article discusses various options for using the PSA test to more effectively screen African American men. In general, testing starting at age 40 is recommended using an upper limit of normal for PSA at 2.0 to 2.5 ng/mL for men between 40 and 49 years of age. In older men, maintaining this lower PSA threshold is reasonable to optimize curable cancer; however, published guidelines of 0 to 4.0, 0 to 4.5, and 0 to 5.5 ng/mL in African American men in their 50s, 60s, and 70s, respectively, are also recognized to balance the sensitivity and specificity of testing. Population-based prospective clinical trials of African American men are needed to further fine-tune the use of PSA in early detection, and to assess whether screening will improve the disease-specific mortality of prostate cancer in the population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Boring CC, Squires TS, Health CW: Cancer statistics for African Americans. CA Cancer J Clin 1993, 43:7–17.

    PubMed  CAS  Google Scholar 

  2. Kosary CL, Ries LAG, Miller BA, et al.: SEER cancer statistics review, 1973–1992: table and graphs. National Cancer Institute. National Institutes of Health Pub. No. 96-2789, 1995.

  3. Morton, RA, Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994, 44:637–645.

    Article  PubMed  Google Scholar 

  4. Aronson WJ, Freeland ST: Editorial: Can we lower the mortality of black men with prostate cancer? J Urol 2000, 163:150–151. Important study.

    Article  PubMed  CAS  Google Scholar 

  5. Cooper R, David R: The biologic concept of race and the application to public health and epidemiology. J Health Polit Policy Law 1986, 11:97–116.

    PubMed  CAS  Google Scholar 

  6. Osborne NG, Feit MD: The use of race in medical research. JAMA 1992, 267:275–279.

    Article  PubMed  CAS  Google Scholar 

  7. Witzig R: The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med 1996, 125:675–679.

    PubMed  CAS  Google Scholar 

  8. Brawley OW, Freeman HP: Race and outcomes: Is this the end of the beginning for minority health research? JNCI 1999, 91:1908–1909.

    Article  PubMed  CAS  Google Scholar 

  9. Robinson SB, Ashley M, and Haynes MA: Attitudes of African Americans regarding screening for prostate cancer. J Natl Med Assoc 1996, 88:241–246.

    PubMed  CAS  Google Scholar 

  10. Robinson SB, Ashley M, Haynes MA: Attitudes of African Americans regarding prostate cancer clinical trials. J Community Health 1996, 21:77–87.

    Article  PubMed  CAS  Google Scholar 

  11. Abbott RR, Taylor DK, Barber K: A comparison of prostate knowledge of African American and Caucasian men: changes from prescreening baseline to post intervention. Cancer J Sci Am 1998, 4:175–177.

    PubMed  CAS  Google Scholar 

  12. Bennett CL, Ferreira MR, Davis TC, et al.: Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 1998, 16:3101–3104.

    PubMed  CAS  Google Scholar 

  13. Guidry JJ, Fagan P, Walker V: Cultural sensitivity and readability of breast and prostate printed cancer education materials targeting African Americans. J Nat Med Assoc 1998, 90:165–169.

    CAS  Google Scholar 

  14. Myers RE, Chodak GW, Wolf TA, et al.: Adherence by African American men to prostate cancer education and early detection. Cancer 1999, 86:88–104.

    Article  PubMed  CAS  Google Scholar 

  15. Weinrich SP, Boyd MD, Weinrich M, et al.: Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. J Cancer Educ 1998, 13:213–129.

    PubMed  CAS  Google Scholar 

  16. Powell IJ, Heilbrun L, Littrup P, et al.: Outcomes of African American men screened for prostate cancer. The Detroit Education and Early Detection study. J Urol 1998, 158:146–149.

    Article  Google Scholar 

  17. Moul JW: Editorial comment to outcomes of African American men screened for prostate cancer: The Detroit Education and Early Detection Study. J Urol 1997, 158:149.

    Article  Google Scholar 

  18. Mouton CP: Special health considerations in African-American elders. Am Family Physician 1997, 55:1243–1253.

    CAS  Google Scholar 

  19. McCoy-Sibley RI, Sibley AF: Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African Americans. J Natl Med Assoc 1997, 89:318–323.

    Google Scholar 

  20. Woolf SH, Screening for prostate cancer with prostatespecific antigen. An examination of the evidence. N Engl J Med 1995, 333:1401–1405.

    Article  PubMed  CAS  Google Scholar 

  21. Barry MJ, Robert RG: Indications for PSA testing. JAMA 1997, 277:955.

    Article  PubMed  CAS  Google Scholar 

  22. American College of Physicians. Screening for Prostate Cancer. Ann Intern Med 1997, 126:480-484.

  23. Von Eschenbach A, Ho R, Murphy GP, et al.: American Cancer Society guidelines for the early detection of prostate cancer. Cancer 1997, 80:1805–1807.

    Article  Google Scholar 

  24. Hankey BF, Feuer EJ, Clegg LX, et al.: Cancer surveillance series: Interpreting trends in prostate cancer-Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999, 91:1017–1024.

    Article  PubMed  CAS  Google Scholar 

  25. Etzioni R, Legler JM, Feuer EJ, et al.: Cancer surveillance series: Interpreting trends in prostate cancer-Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999, 91:1033–1039.

    Article  PubMed  CAS  Google Scholar 

  26. Labrie F, Candas B, Dupont A, et al.: Screening decreases prostate cancer death: First analysis of the 1998 Quebec prospective randomized controlled trial. Prostate 1999, 38(2):83–91.

    Article  PubMed  CAS  Google Scholar 

  27. Roach J, Won M, Keller J, Perez CA, et al.: The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group Protocols (1976-1985). Int J Radiat Oncol Bio Phys 1992, 24:441–449.

    Google Scholar 

  28. Optenberg SA, Thompson IM, Friedrichs P, et al.: Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 1995, 274:1599.

    Article  PubMed  CAS  Google Scholar 

  29. Eastham JA, Kattani MW: Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol 2000, 163:143–145. Key study.

    Article  PubMed  CAS  Google Scholar 

  30. Powell IJ, Banerjee M, Sakr W, et al.: Should African American men be tested for prostate carcinoma at an earlier age than white men? Cancer 1999, 85:472–477.

    Article  PubMed  CAS  Google Scholar 

  31. Vijayakumar S, Karrison T, Weichselbaum RR, et al.: Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidermiol Biomarkers Prev 1992, 1:541–545.

    CAS  Google Scholar 

  32. Staggers FM, DeAntoni EP, Crawford ED, et al.: A profile of African-American participants in Prostate Cancer Awareness Week (PCAW) 1992. J Urol 1994, 151:291(A255).

    Google Scholar 

  33. Bullock A, Smith DS, Basler J, et al.: Racial differences in prostate cancer detection and staging. J Urol 1994, 151:291(A#57).

    Google Scholar 

  34. Moul JW, Sesterhenn IA, Connelly RR, et al.: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J Am Med Assoc 1995, 274:1277–1281.

    Article  CAS  Google Scholar 

  35. Vijayakumar S, Weichselbaum RR, Vaida F, et al.: Prostate specific antigen levels in African Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am 1996, 2:225–233.

    PubMed  CAS  Google Scholar 

  36. Abdalla I, Ray P, Ray V, et al.: Comparison of serum prostatespecific antigen levels and PSA density in African American, white, and Hispanic men without prostate cancer. Urology 1998, 51:300–305.

    Article  PubMed  CAS  Google Scholar 

  37. Abdalla I, Ray P, Vaida F, Vijayakumar S: Racial differences in prostate-specific antigen levels and prostate specific antigen densities in patients with prostate cancer. Am J Clin Oncol 1999, 22:537–541.

    Article  PubMed  CAS  Google Scholar 

  38. Vijayakumar S, Winter K, Sause W, et al.: Prostate specific antigen levels are higher in African Americans than in white patients in a multicenter registration study: results of RTOG 94-12. Int J Radiat Oncol Biol Phys 1998, 40:17–25.

    Article  PubMed  CAS  Google Scholar 

  39. Vijayakumar S, Vaida F, Weichselbaum RR, Hellman S: Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am 1998, 4:27–34.

    PubMed  CAS  Google Scholar 

  40. Moul JW, Connelly RR, Mooneyhan RM, et al.: Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 1999, 162:394–397. An important study.

    Article  PubMed  CAS  Google Scholar 

  41. Zhang W, Sesterhenn IA, Connelly RR, et al.: Inflammatory infiltrate (prostatitis) in whole-mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference prostate-specific antigen. J Urol 2000, 163:131–136.

    Article  PubMed  CAS  Google Scholar 

  42. Eastman JA, May RA, Whatley T, et al.: Clinical characteristics and biopsy specimen features in African American and white men without prostate cancer. J Natl Cancer Inst 1998, 90:756–760.

    Article  Google Scholar 

  43. Sakr WA, Grignon DJ, Haas GP, et al.: Epidemiology of high-grade intraepithelial neoplasia. Pathol Res Pract 1995, 191:838–841.

    PubMed  CAS  Google Scholar 

  44. Sakr WA, Wheeler TM, Blute M, et al.: International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma: staging and reporting of prostate cancer sampling of the radical prostatectomy specimen. Cancer 1996, 78:366–368.

    Article  PubMed  CAS  Google Scholar 

  45. Ross RK, Bernstein L, Lobo RA, et al.: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Cancer 1992, 339:887.

    CAS  Google Scholar 

  46. Irvine RA, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995, 55:1937–1940.

    PubMed  CAS  Google Scholar 

  47. Smith DS, Bullock AD, Catalona WJ, Herschan JD: Racial differences in a prostate cancer screening study. J Urol 1996, 156:1366–69.

    Article  PubMed  CAS  Google Scholar 

  48. Smith DS, Bullock AD, Catalona WJ: Racial differences in operating characteristics of prostate cancer screening tests. J Urol 1997, 58:1861–1866.

    Article  Google Scholar 

  49. Smith DS, Carvalhal GF, Mager DE, et al.: Use of lower prostate-specific antigen cut-offs for prostate cancer screening in black and white men. J Urol 1998, 160:1734–1738.

    Article  PubMed  CAS  Google Scholar 

  50. Morgan TO, Jacobson SJ, McCarthy WF, et al.: Age-specific reference ranges for prostate-specific antigen in black men. New Engl J Med 1996, 335:304–310.

    Article  PubMed  CAS  Google Scholar 

  51. Oesterling JE, Jacobson ST, Cjite CG, et al.: Serum prostatespecific antigen in a community-based population of healthy men. JAMA 1993, 270:860–864.

    Article  PubMed  CAS  Google Scholar 

  52. Littrup PJ: Prostate cancer in African-American men [editorial]. 1997, 31:139–141.

    CAS  Google Scholar 

  53. Littrup PJ, Sparschu RA: Transrectal ultrasound and prostate cancer risks: The “tailored” prostate biopsy. Cancer 1995, 75(suppl):1805–1813.

    Article  Google Scholar 

  54. Powell IJ, Banerjee M, Novallo M, et al.: Should the age-specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol 2000, 163:146–149.

    Article  PubMed  CAS  Google Scholar 

  55. Moul JW: Curability of prostate cancer in African Americans: Implications for Neoadjuvant/Adjuvant hormonal therapy. Mol Urol 1998, 2:209.

    CAS  Google Scholar 

  56. Moul JW: PSA thresholds for prostate cancer detection. JAMA 1997, 278:699.

    Article  PubMed  CAS  Google Scholar 

  57. Carter HB, et al.: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997, 277:1456–1460.

    Article  PubMed  CAS  Google Scholar 

  58. Catalona WJ: Screening for prostate cancer [letter]. N Eng J Med 1996, 334:666–667.

    Article  Google Scholar 

  59. Bullock AD, Harmon T, Smith DS, Basler JW: Prostate cancer screening in younger men [abstract]. J Urol 1997, S66:157.

    Google Scholar 

  60. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ngmL and benign prostate examination. JAMA 1997, 277:1452–1455.

    Article  PubMed  CAS  Google Scholar 

  61. Preston DM, Levin LI, Jacobson, et al.: Prostate specific antigen levels in young Caucasian and African American men age 20–45. Urology 2000, in press.

  62. Moul JW, Connelly RR, Barko WF, Vaitkus M: Should healthy Caucasian men between the age of 40–49 be screened for prostate cancer: a Department of Defense (DoD) Center for Prostate Disease Research (CPDR) and Army Physical Fitness Research Institute (APFRI) prospective study at the U.S. Army War College (USAWC). J Urol 2000, 163(suppl 4):90, abstract #393.

    Google Scholar 

  63. Hartzell J, Kao C, Moul JW: Age-adjusted prostate-specific antigen (PSA) in men between 30–59 years of age: National Defense University study. Publication pending.

  64. Moul JW: A PSA cutoff of 4 is too high for many men. Contemp Urol 1999, 11:15–32.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Prostate Disease Research, 1530 East Jefferson Street, 20852, Rockville, MD, USA

    Judd W. Moul MD FACS

Authors
  1. Judd W. Moul MD FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moul, J.W. Screening for prostate cancer in african americans. Curr Urol Rep 1, 57–64 (2000). https://doi.org/10.1007/s11934-000-0036-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-000-0036-y

Keywords

Search

Navigation